Quantum Biopharma Ltd. | WebDisclosure

PRESS RELEASE

published on 12/20/2024 at 15:15, 1 year 10 months ago

Quantum Biopharma Diversifies Treasury With the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency
Quantum BioPharma Ltd. purchases $1,000,000 Bitcoin and other cryptocurrencies, allows cryptocurrency transactions, emphasizing compliance and potential returns for shareholders

Bitcoin Compliance Investment Cryptocurrency Quantum BioPharma
BRIEF

published on 12/14/2024 at 01:05, 1 year 10 months ago

Quantum BioPharma conclut la première tranche de son offre

Première Tranche Biopharmacie Quantique Unités D'obligations Développement Du Capital Dollars Canadiens
BRIEF

published on 12/14/2024 at 01:05, 1 year 10 months ago

Quantum BioPharma Concludes Initial Tranche of Offering

First Tranche Capital Development Quantum BioPharma Canadian Dollars Debenture Units
PRESS RELEASE

published on 12/14/2024 at 01:00, 1 year 10 months ago

Quantum Biopharma Announces Closing of First Tranche
Quantum BioPharma closes initial tranche of offering, issuing 500 Debenture Units for $500,000. Proceeds for business development and working capital. Securities subject to statutory hold period

Working Capital Statutory Hold Period Quantum BioPharma Debenture Units Tranche Offering
BRIEF

published on 12/10/2024 at 13:35, 1 year 10 months ago

Quantum Biopharma avance dans l'essai clinique Lucid-MS

Recherche Biopharmaceutique Biopharmacie Quantique Examen De Sécurité Essai Lucid-MS Progrès Clinique
BRIEF

published on 12/10/2024 at 13:35, 1 year 10 months ago

Quantum Biopharma Moves Forward in Lucid-MS Clinical Trial

Biopharmaceutical Research Quantum BioPharma Lucid-MS Trial Clinical Advancement Safety Review
PRESS RELEASE

published on 12/10/2024 at 13:30, 1 year 10 months ago

Quantum Biopharma Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-MS)
Quantum BioPharma announces approval to proceed with dosing of second cohort in Lucid-21-302 trial. Company focused on innovative treatments for neurodegenerative disorders

Drug Development Neurodegenerative Disorders Quantum BioPharma Lucid-21-302 Trial Safety Review Committee
BRIEF

published on 12/05/2024 at 13:35, 1 year 10 months ago

Quantum BioPharma Launches Private Placement for $5 Million

Private Placement Convertible Debenture Canadian Market Investment Offering Quantum BioPharma
BRIEF

published on 12/05/2024 at 13:35, 1 year 10 months ago

Quantum BioPharma lance un placement privé de 5 millions de dollars

Placement Privé Marché Canadien Obligation Convertible Biopharmacie Quantique Offre D'investissement
PRESS RELEASE

published on 12/05/2024 at 13:30, 1 year 10 months ago

Quantum Biopharma Announces Non-Brokered Private Placement of Convertible Debenture Units for Gross Proceeds of Up to $5 Million
Quantum BioPharma announces a non-brokered private placement offering of convertible debenture units. Proceeds for business development and working capital

Private Placement Working Capital Business Development Quantum BioPharma Debenture Units

Published on 10/26/2026 at 14:10, 40 minutes ago

China XLX Announces 2026 9M Results
Published on 10/26/2026 at 13:30, 1 hour 20 minutes ago

Stabilis Solutions Announces Third Quarter 2026 Conference Call and Webcast Date
Published on 10/26/2026 at 13:00, 1 hour 50 minutes ago

BTU Commences Initial Drill Program on Hubcap Project Adjacent to RPX in Wawa
Published on 10/26/2026 at 13:00, 1 hour 50 minutes ago

GameSquare Closes FanEngine Transaction
Published on 10/26/2026 at 12:30, 2 hours 20 minutes ago

Longview Capital Announces Voluntary TSXV Delisting

View all ACCESSWIRE

Published on 10/26/2026 at 14:36, 13 minutes ago

Original-Research: Vossloh AG (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 10/26/2026 at 14:33, 16 minutes ago

UPDATE ON STRATEGIC TRANSACTION, FURTHER PORTFOLIO DISPOSAL PROCESS AND CONTINUED LENDER SUPPORT
Published on 10/26/2026 at 14:28, 21 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 10/26/2026 at 14:28, 21 minutes ago

Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 10/26/2026 at 14:27, 22 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc

View all EQS

Published on 10/26/2026 at 11:27, 3 hours 22 minutes ago

261026 BENETEAU Transactions sur actions propres
Published on 10/26/2026 at 07:30, 7 hours 20 minutes ago

EURAZEO’S SUPERVISORY BOARD APPOINTS CHRISTOPHE BAVIÈRE AS CHAIRMAN OF THE EXECUTIVE BOARD AND CEO
Published on 10/26/2026 at 07:30, 7 hours 20 minutes ago

LE CONSEIL DE SURVEILLANCE D’EURAZEO NOMME M. CHRISTOPHE BAVIERE PRESIDENT DU DIRECTOIRE
Published on 10/23/2026 at 20:33, 2 days 18 hours ago

Déclaration hebdomadaire d'opérations effectuées du 19 au 23 octobre 2026
Published on 10/23/2026 at 20:33, 2 days 18 hours ago

Disclosure of transactions in own shares from October 19 to October 23, 2026

View all LES ECHOS COMFI WIRE

News